• Home
  • > Media & Investors
  • > Media Relations
  • > Press Releases
  • > The National Institutes of Biomedical Innovation, Health and Nutrition, Daiichi Sankyo,and Mitsubishi UFJ Capital Announce Open Innovation Research on New Cancer Immunotherapy

For Immediate Release

2017.03.16

National Institutes of Biomedical Innovation, Health and Nutrition
Daiichi Sankyo Company, Limited
Mitsubishi UFJ Capital Co., Ltd.

The National Institutes of Biomedical Innovation, Health and Nutrition, Daiichi Sankyo,and Mitsubishi UFJ Capital Announce Open Innovation Research on New Cancer Immunotherapy

Tokyo and Osaka, Japan (March 16, 2017) - National Institutes of Biomedical Innovation, Health and Nutrition (Director General: Yoshihiro Yoneda; Ibaraki-shi, Osaka; hereinafter “NIBIOHN”), Daiichi Sankyo Company, Limited (Representative Director, President and CEO: George Nakayama; head office: Chuo-ku, Tokyo; hereinafter “Daiichi Sankyo”), and Mitsubishi UFJ Capital Co., Ltd. (President: Muneki Handa; head office: Chuo-ku, Tokyo; hereinafter “Mitsubishi UFJ Capital”) today announced that they will launch open innovation research (“the research”) on new cancer immunotherapy.

 

To carry out the research, a new company called OiDE Adjubilee, Inc. (head office: Chuo-ku, Tokyo; hereinafter “Adjubilee”) was established and wholly funded by the OiDE Fund Investment Limited Partnership (“OiDE Fund”), operated by Mitsubishi UFJ Capital.

 

If the goals of the two-year joint research are achieved, Daiichi Sankyo will purchase all Adjubilee stock in order to continue research and development of the new cancer immunotherapy on its own, paying sales royalties to NIBIOHN following a successful product launch.

 

This research into new cancer immunotherapy is the second OiDE Fund investment, and Daiichi Sankyo and Mitsubishi UFJ Capital plan to continue to promote open innovation activities to develop new drug discovery platforms using the OiDE Fund.

 

*OiDE (Open innovation for the Development of Emerging technologies) Fund

A fund jointly established by Mitsubishi UFJ Capital and Daiichi Sankyo in 2013, operated by Mitsubishi UFJ Capital

 

 

[Schematic view]

 

 

Contact information

Department of Strategic Planning, National Institutes of Biomedical Innovation, Health and Nutrition

TEL: +81-72-641-9832

Corporate Communications Department, Daiichi Sankyo Co., Ltd.

TEL: +81-3-6225-1126

Planning Division, Mitsubishi UFJ Capital Co., Ltd.

TEL: +81-3-5205-8581